Overview
AbbVie Inc., based in the United States, operates predominantly within the pharmaceutical industry. Established as a spin-off from Abbott Laboratories in 2013, AbbVie focuses on developing and marketing advanced therapies for complex and serious medical conditions. The company has a robust portfolio of key products, notably Humira, for autoimmune diseases, and Imbruvica, for cancer treatment. AbbVie's strategy emphasizes both organic growth through its pipeline of biopharmaceutical products and growth through strategic acquisitions, as seen in its acquisition of Allergan in 2020. This transaction significantly enhanced AbbVie's presence in immunology, oncology, neuroscience, eye care, and women's health, further diversifying its biopharmaceutical offerings.
AI+ Ask Fintel’s AI assistant about AbbVie Inc..
Thinking about good questions…
Basic Stats
The Factor Analysis chart (below right) shows a view of AbbVie Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | 1,771.00 MM |
| Earnings Date | |
| EPS (TTM) | 2.12 |
| Dividend Yield | |
| Ex-Dividend Date | 2025-07-15 |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | |
| Beta | |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | 0.03 |
| ROE | 0.47 |
| ROIC | 0.05 |
| CROIC | -0.09 |
| OCROIC | 0.27 |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | 38.05 /100 |
| Profitability | 54.81 /100 |
| Quality Score | 78.72 /100 |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | 20.23 /100 |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE | 6.00 /9 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for AbbVie Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2025-02-03 | Wells Fargo | Overweight | Overweight | Maintains |
| 2025-02-03 | UBS | Neutral | Neutral | Maintains |
| 2025-02-03 | Truist Securities | Buy | Buy | Maintains |
| 2025-02-03 | Citigroup | Buy | Buy | Maintains |
| 2024-11-04 | Argus Research | Hold | Buy | Upgrade |
| 2025-02-03 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2025-02-03 | BMO Capital | Outperform | Outperform | Maintains |
| 2025-02-03 | Guggenheim | Buy | Buy | Maintains |
| 2025-02-03 | Raymond James | Outperform | Outperform | Reiterate |
| 2024-11-12 | BMO Capital | Outperform | Outperform | Maintains |
| 2024-11-12 | Citigroup | Buy | Buy | Maintains |
| 2024-11-12 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2025-01-08 | Truist Securities | Buy | Buy | Maintains |
| 2024-11-22 | Leerink Partners | Market Perform | Outperform | Upgrade |
| 2024-08-12 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2024-08-05 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-07-26 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-07-26 | Truist Securities | Buy | Buy | Reiterate |
| 2024-07-26 | Wells Fargo | Overweight | Overweight | Maintains |
| 2024-07-26 | Barclays | Overweight | Overweight | Maintains |
| 2024-07-19 | BMO Capital | Outperform | Outperform | Maintains |
| 2024-07-11 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2024-07-09 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-07-02 | Piper Sandler | Overweight | Overweight | Maintains |
| 2024-06-20 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-06-18 | Piper Sandler | Overweight | Overweight | Maintains |
| 2024-06-05 | HSBC | Hold | Buy | Upgrade |
| 2024-05-17 | Cantor Fitzgerald | Overweight | Initiate | |
| 2024-04-29 | Barclays | Overweight | Overweight | Maintains |
| 2024-04-29 | BMO Capital | Outperform | Outperform | Maintains |
| 2024-03-27 | Barclays | Overweight | Overweight | Maintains |
| 2024-03-22 | Guggenheim | Buy | Buy | Maintains |
| 2024-02-06 | Raymond James | Outperform | Maintains | |
| 2024-02-06 | Truist Securities | Buy | Buy | Maintains |
| 2024-02-05 | BMO Capital | Outperform | Outperform | Maintains |
| 2024-02-05 | Raymond James | Outperform | Outperform | Maintains |
| 2024-02-05 | Barclays | Overweight | Overweight | Maintains |
| 2024-01-29 | William Blair | Market Perform | Outperform | Upgrade |
| 2024-01-23 | Barclays | Overweight | Overweight | Maintains |
| 2023-12-18 | HSBC | Buy | Hold | Downgrade |
| 2023-12-11 | Goldman Sachs | Neutral | Buy | Upgrade |
| 2023-12-01 | Raymond James | Outperform | Outperform | Maintains |
| 2023-11-09 | Deutsche Bank | Hold | Initiate | |
| 2023-10-30 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2023-10-30 | Barclays | Equal-Weight | Overweight | Upgrade |
| 2023-10-11 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2023-09-29 | Raymond James | Outperform | Initiate | |
| 2023-07-28 | Piper Sandler | Overweight | Overweight | Maintains |
| 2023-07-25 | William Blair | Market Perform | Initiate | |
| 2023-07-14 | HSBC | Buy | Initiate | |
| 2023-07-11 | Morgan Stanley | Overweight | Overweight | Reiterate |
| 2023-04-28 | Guggenheim | Buy | Maintains | |
| 2023-04-28 | Morgan Stanley | Overweight | Maintains | |
| 2023-04-28 | Wells Fargo | Overweight | Maintains | |
| 2023-04-10 | Morgan Stanley | Overweight | Maintains | |
| 2023-04-05 | Argus Research | Buy | Hold | Downgrade |
| 2023-03-01 | Guggenheim | Buy | Initiate | |
| 2023-02-22 | Wolfe Research | Outperform | Peer Perform | Downgrade |
| 2023-02-10 | SVB Leerink | Underperform | Market Perform | Upgrade |
| 2023-02-10 | Atlantic Equities | Neutral | Maintains | |
| 2023-02-10 | Morgan Stanley | Overweight | Maintains | |
| 2023-02-10 | Piper Sandler | Overweight | Maintains | |
| 2023-02-06 | BMO Capital | Outperform | Maintains | |
| 2023-01-17 | Piper Sandler | Overweight | Maintains | |
| 2022-12-06 | Morgan Stanley | Overweight | Maintains | |
| 2022-11-18 | Credit Suisse | Outperform | Initiate | |
| 2022-11-08 | Societe Generale | Buy | Hold | Downgrade |
| 2022-10-31 | Atlantic Equities | Neutral | Maintains | |
| 2022-10-31 | BMO Capital | Outperform | Maintains | |
| 2022-10-31 | Morgan Stanley | Overweight | Maintains | |
| 2022-10-31 | Barclays | Equal-Weight | Maintains | |
| 2022-10-11 | Morgan Stanley | Overweight | Maintains | |
| 2022-09-30 | SVB Leerink | Underperform | Maintains | |
| 2022-08-24 | Argus Research | Buy | Maintains | |
| 2022-08-01 | UBS | Neutral | Maintains | |
| 2022-08-01 | Morgan Stanley | Overweight | Maintains | |
| 2022-08-01 | Barclays | Equal-Weight | Maintains | |
| 2022-08-01 | Atlantic Equities | Neutral | Maintains | |
| 2022-07-08 | Morgan Stanley | Overweight | Maintains | |
| 2022-05-23 | SVB Leerink | Underperform | Initiate | |
| 2022-05-02 | Morgan Stanley | Overweight | Maintains | |
| 2022-05-02 | Wells Fargo | Overweight | Maintains | |
| 2022-04-25 | BMO Capital | Outperform | Maintains | |
| 2022-04-12 | Barclays | Equal-Weight | Maintains | |
| 2022-04-12 | Goldman Sachs | Neutral | Maintains | |
| 2022-04-06 | Morgan Stanley | Overweight | Maintains | |
| 2022-02-28 | UBS | Buy | Neutral | Downgrade |
| 2022-02-04 | Mizuho | Buy | Maintains | |
| 2022-02-03 | Barclays | Equal-Weight | Maintains | |
| 2022-01-24 | Morgan Stanley | Overweight | Maintains | |
| 2022-01-20 | Barclays | Equal-Weight | Maintains | |
| 2022-01-12 | BMO Capital | Outperform | Maintains | |
| 2022-01-05 | Mizuho | Buy | Maintains | |
| 2021-12-17 | Goldman Sachs | Neutral | Initiate | |
| 2021-12-09 | Wells Fargo | Overweight | Initiate | |
| 2021-11-23 | Societe Generale | Hold | Buy | Upgrade |
| 2021-11-01 | Barclays | Equal-Weight | Maintains | |
| 2021-11-01 | Morgan Stanley | Overweight | Maintains | |
| 2021-11-01 | SVB Leerink | Outperform | Maintains | |
| 2021-08-20 | SVB Leerink | Outperform | Maintains | |
| 2021-08-02 | Mizuho | Buy | Maintains | |
| 2021-08-02 | SVB Leerink | Outperform | Maintains | |
| 2021-05-03 | BMO Capital | Outperform | Maintains | |
| 2021-03-30 | SVB Leerink | Outperform | Maintains | |
| 2021-02-04 | SVB Leerink | Outperform | Maintains | |
| 2021-01-28 | Morgan Stanley | Overweight | Maintains | |
| 2020-12-16 | SVB Leerink | Outperform | Maintains | |
| 2020-11-30 | Morgan Stanley | Overweight | Maintains | |
| 2020-11-18 | BMO Capital | Outperform | Initiate | |
| 2020-11-10 | Bernstein | Outperform | Initiate | |
| 2020-11-02 | SVB Leerink | Outperform | Maintains | |
| 2020-10-23 | Truist Securities | Buy | Initiate | |
| 2020-10-16 | JP Morgan | Overweight | Maintains | |
| 2020-09-29 | Berenberg | Hold | Initiate | |
| 2020-09-02 | Citigroup | Buy | Maintains | |
| 2020-08-20 | Morgan Stanley | Overweight | Maintains | |
| 2020-08-03 | Mizuho | Buy | Maintains | |
| 2020-08-03 | RBC Capital | Outperform | Maintains | |
| 2020-06-23 | Atlantic Equities | Neutral | Overweight | Upgrade |
| 2020-06-02 | Argus Research | Hold | Buy | Upgrade |
| 2020-05-18 | B of A Securities | Neutral | Reiterate | |
| 2020-05-12 | JP Morgan | Neutral | Overweight | Upgrade |
| 2020-05-11 | Morgan Stanley | Overweight | Reiterate | |
| 2020-05-11 | SVB Leerink | Outperform | Maintains | |
| 2020-05-04 | SVB Leerink | Outperform | Maintains | |
| 2020-04-20 | RBC Capital | Sector Perform | Outperform | Upgrade |
| 2020-04-13 | UBS | Buy | Maintains | |
| 2020-03-23 | Societe Generale | Buy | Hold | Downgrade |
| 2020-02-27 | Barclays | Equal-Weight | Initiate | |
| 2020-02-18 | Cowen & Co. | Outperform | Maintains | |
| 2020-02-10 | Mizuho | Buy | Maintains | |
| 2020-02-06 | Mizuho | Buy | Initiate | |
| 2019-12-26 | Cowen & Co. | Outperform | Maintains | |
| 2019-11-20 | Citi | Buy | Maintains | |
| 2019-11-19 | UBS | Buy | Maintains | |
| 2019-09-26 | Citigroup | Neutral | Buy | Upgrade |
| 2019-09-12 | UBS | Neutral | Buy | Upgrade |
| 2019-09-04 | Piper Jaffray | Overweight | Maintains | |
| 2019-08-20 | Piper Jaffray | Neutral | Overweight | Upgrade |
| 2019-06-26 | SVB Leerink | Market Perform | Outperform | Upgrade |
| 2019-05-28 | Goldman Sachs | Neutral | Initiate | |
| 2019-04-29 | BMO Capital | Underperformer | Market Perform | Upgrade |
| 2019-01-03 | Bank of America | Buy | Neutral | Downgrade |
| 2018-12-26 | Standpoint Research | Buy | Initiate | |
| 2018-11-06 | Argus | Buy | Buy | Maintains |
| 2018-11-05 | BMO Capital | Underperform | Underperform | Maintains |
| 2018-10-04 | Bank of America | Buy | Buy | Maintains |
| 2018-08-22 | Bank of America | Buy | Buy | Maintains |
| 2018-07-30 | Bank of America | Buy | Buy | Maintains |
| 2018-07-12 | Berenberg | Hold | Initiate | |
| 2018-06-11 | Argus | Buy | Buy | Maintains |
| 2018-06-01 | PiperJaffray | Overweight | Neutral | Downgrade |
| 2018-05-30 | Credit Suisse | Neutral | Underperform | Downgrade |
| 2018-05-23 | BMO Capital | Underperform | Underperform | Maintains |
| 2018-04-30 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2018-04-27 | Credit Suisse | Neutral | Neutral | Maintains |
| 2018-04-05 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2018-03-23 | BMO Capital | Underperform | Underperform | Maintains |
| 2018-02-02 | Argus | Buy | Maintains | |
| 2018-01-30 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2018-01-30 | BMO Capital | Market Perform | Underperform | Downgrade |
| 2018-01-29 | Leerink Swann | Outperform | Market Perform | Downgrade |
| 2017-11-16 | BMO Capital | Market Perform | Maintains | |
| 2017-10-30 | Leerink Swann | Outperform | Maintains | |
| 2017-10-13 | Barclays | Equal-Weight | Maintains | |
| 2017-10-13 | UBS | Neutral | Maintains | |
| 2017-10-11 | Cowen & Co. | Market Perform | Outperform | Upgrade |
| 2017-10-05 | Leerink Swann | Outperform | Maintains | |
| 2017-10-02 | Leerink Swann | Outperform | Maintains | |
| 2017-09-25 | UBS | Buy | Neutral | Downgrade |
| 2017-09-15 | Jefferies | Buy | Maintains | |
| 2017-08-17 | Evercore ISI Group | Outperform | Initiate | |
| 2017-07-17 | Jefferies | Buy | Maintains | |
| 2017-07-17 | Deutsche Bank | Hold | Maintains | |
| 2017-03-10 | Goldman Sachs | Buy | Buy | Maintains |
| 2016-11-28 | Citigroup | Buy | Neutral | Downgrade |
| 2016-10-31 | Credit Suisse | Outperform | Neutral | Downgrade |
| 2016-10-18 | Leerink Swann | Market Perform | Initiate | |
| 2016-09-08 | JP Morgan | Overweight | Neutral | Downgrade |
| 2016-09-02 | Raymond James | Outperform | Initiate | |
| 2016-06-10 | BMO Capital | Outperform | Market Perform | Downgrade |
| 2016-06-08 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2016-06-06 | Cowen & Co. | Outperform | Market Perform | Downgrade |
| 2016-04-06 | Societe Generale | Sell | Initiate | |
| 2016-03-15 | Deutsche Bank | Hold | Initiate | |
| 2016-03-07 | Goldman Sachs | Buy | Maintains | |
| 2016-02-23 | Citigroup | Neutral | Buy | Upgrade |
| 2016-02-05 | William Blair | Outperform | Initiate | |
| 2016-01-14 | Jefferies | Buy | Maintains | |
| 2015-12-18 | Atlantic Equities | Neutral | Initiate | |
| 2015-12-01 | Barclays | Overweight | Equal-Weight | Downgrade |
| 2015-11-02 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| 2015-07-29 | Deutsche Bank | Buy | Maintains | |
| 2015-07-22 | SunTrust Robinson Humphrey | Buy | Initiate | |
| 2015-06-16 | PiperJaffray | Overweight | Initiate | |
| 2015-06-08 | Jefferies | Buy | Maintains | |
| 2015-04-24 | BMO Capital | Outperform | Maintains | |
| 2015-04-13 | BMO Capital | Market Perform | Outperform | Upgrade |
| 2015-02-09 | Citigroup | Sell | Initiate | |
| 2015-02-03 | Jefferies | Buy | Maintains | |
| 2015-01-16 | Barclays | Overweight | Maintains | |
| 2015-01-15 | Jefferies | Buy | Maintains | |
| 2015-01-09 | Bank of America | Buy | Neutral | Downgrade |
| 2014-12-11 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2014-12-04 | Jefferies | Buy | Maintains | |
| 2014-11-14 | Deutsche Bank | Outperform | Initiate | |
| 2014-11-04 | Jefferies | Buy | Maintains | |
| 2014-11-03 | JP Morgan | Overweight | Maintains | |
| 2014-10-17 | ISI Group | Buy | Initiate | |
| 2014-10-02 | Guggenheim | Buy | Initiate | |
| 2014-08-06 | Credit Suisse | Outperform | Maintains | |
| 2014-07-28 | UBS | Neutral | Buy | Upgrade |
| 2014-07-18 | Jefferies | Buy | Maintains | |
| 2014-07-14 | Jefferies | Buy | Maintains | |
| 2014-07-02 | Barclays | Equal-weight | Overweight | Upgrade |
| 2014-06-20 | Credit Suisse | Outperform | Maintains | |
| 2014-05-07 | Morgan Stanley | Equal-weight | Overweight | Upgrade |
| 2014-04-24 | Bank of America | Buy | Maintains | |
| 2014-04-14 | Jefferies | Buy | Maintains | |
| 2014-02-21 | Bank of America | Buy | Maintains | |
| 2014-01-27 | Morgan Stanley | Equal-Weight | Maintains | |
| 2013-12-31 | Bank of America | Buy | Maintains | |
| 2013-12-19 | Morgan Stanley | Overweight | Equal-weight | Downgrade |
| 2013-10-25 | BMO Capital | Market Perform | Outperform | Upgrade |
| 2013-10-08 | Credit Suisse | Outperform | Initiate | |
| 2013-08-12 | Argus | Buy | Initiate | |
| 2013-06-07 | Jefferies | Buy | Maintains | |
| 2013-05-28 | Jefferies | Buy | Maintains | |
| 2013-05-15 | Cowen & Co. | Outperform | Initiate | |
| 2013-04-29 | BMO Capital | Market Perform | Maintains | |
| 2013-04-22 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| 2013-04-10 | Jefferies | Buy | Maintains | |
| 2013-04-10 | UBS | Neutral | Maintains | |
| 2013-04-09 | Goldman Sachs | Buy | Maintains | |
| 2013-04-05 | BMO Capital | Market Perform | Maintains | |
| 2013-04-01 | BMO Capital | Outperform | Market Perform | Downgrade |
| 2013-03-11 | Bank of America | Buy | Maintains | |
| 2024-10-31 | Citigroup | Buy | Buy | Maintains |
| 2024-10-31 | UBS | Neutral | Neutral | Maintains |
| 2024-10-17 | BMO Capital | Outperform | Outperform | Maintains |
| 2024-10-17 | Bernstein | Market Perform | Initiate | |
| 2024-08-23 | Piper Sandler | Overweight | Overweight | Maintains |
| 2024-12-17 | Piper Sandler | Overweight | Overweight | Maintains |
| 2024-11-13 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-11-15 | Wolfe Research | Outperform | Initiate | |
| 2025-01-28 | Citigroup | Buy | Buy | Maintains |
| 2024-11-06 | Guggenheim | Buy | Buy | Maintains |
| 2025-04-29 | Guggenheim | Buy | Buy | Maintains |
| 2024-10-31 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2024-10-25 | Citigroup | Buy | Buy | Maintains |
| 2024-10-07 | TD Cowen | Buy | Buy | Maintains |
| 2024-10-07 | Barclays | Overweight | Overweight | Maintains |
| 2025-03-05 | Wells Fargo | Overweight | Overweight | Maintains |
| 2025-08-01 | Guggenheim | Buy | Buy | Maintains |
| 2025-08-01 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2025-08-01 | Raymond James | Outperform | Outperform | Maintains |
| 2024-10-18 | B of A Securities | Neutral | Neutral | Maintains |
| 2024-12-10 | B of A Securities | Neutral | Reiterate | |
| 2024-10-10 | Truist Securities | Buy | Buy | Maintains |
| 2024-10-09 | UBS | Neutral | Neutral | Maintains |
| 2025-03-04 | B of A Securities | Neutral | Neutral | Maintains |
| 2025-04-09 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2025-04-17 | Guggenheim | Buy | Buy | Reiterate |
| 2025-05-14 | Citigroup | Buy | Neutral | Downgrade |
| 2025-04-28 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2025-04-28 | Evercore ISI Group | Outperform | Outperform | Maintains |
| 2025-04-22 | Cantor Fitzgerald | Overweight | Initiate |
